Medpace
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Medpace and other ETFs, options, and stocks.About MEDP
Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. The firm's services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.
CEOAugust James Troendle
CEOAugust James Troendle
Employees5,900
Employees5,900
HeadquartersCincinnati, Ohio
HeadquartersCincinnati, Ohio
Founded1992
Founded1992
Employees5,900
Employees5,900
MEDP Key Statistics
Market cap15.99B
Market cap15.99B
Price-Earnings ratio39.99
Price-Earnings ratio39.99
Dividend yield—
Dividend yield—
Average volume210.10K
Average volume210.10K
High today$571.85
High today$571.85
Low today$561.83
Low today$561.83
Open price$571.85
Open price$571.85
Volume160.37K
Volume160.37K
52 Week high$626.26
52 Week high$626.26
52 Week low$250.05
52 Week low$250.05
Stock Snapshot
With a market cap of 15.99B, Medpace(MEDP) trades at $567.56. The stock has a price-to-earnings ratio of 39.99.
On 2025-12-26, Medpace(MEDP) stock traded between a low of $561.83 and a high of $571.85. Shares are currently priced at $567.56, which is +1.0% above the low and -0.8% below the high.
The Medpace(MEDP)'s current trading volume is 160.37K, compared to an average daily volume of 210.1K.
In the last year, Medpace(MEDP) shares hit a 52-week high of $626.26 and a 52-week low of $250.05.
In the last year, Medpace(MEDP) shares hit a 52-week high of $626.26 and a 52-week low of $250.05.
Analyst ratings
62%
of 13 ratingsBuy
7.7%
Hold
61.5%
Sell
30.8%
People also own
Based on the portfolios of people who own MEDP. This list is generated using Robinhood data, and it’s not a recommendation.